{"product_id":"dna-bcg-matrix","title":"(DNA) Ginkgo Bioworks Holdings, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Ginkgo Bioworks Holdings, Inc. BCG Matrix helps you see how the company’s products or business units are positioned across Stars, Cash Cows, Question Marks, and Dogs. It is used for strategic review, portfolio analysis, and capital allocation decisions, and this page already shows a real preview\/sample of the analysis. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentric by Ginkgo\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eConcentric by Ginkgo fits Stars in the BCG matrix because pathogen surveillance and public health monitoring are growing fast. It uses Ginkgo Bioworks Holdings, Inc.'s cell engineering and data platform to speed detection workflows and improve response time. If contract wins widen, this biosecurity line can move from niche leadership to a larger scale business.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCell engineering foundry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGinkgo Bioworks reported 2024 revenue of $189.3 million, and its cell engineering foundry remains the core platform for designing and building engineered cells. It supports pharma, agriculture, food, consumer goods, and industrial chemicals, giving Ginkgo broad reach across end markets. In a synthetic biology market growing at double-digit rates, the foundry is the closest thing to a BCG Star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma discovery partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDrug discovery partnerships are a key Star for Ginkgo Bioworks Holdings, Inc. because one platform can support many programs, so each new deal adds upside without building a separate product for every customer.\u003c\/p\u003e\n\u003cp\u003eThis model can scale as partner pipelines deepen, and that matters in a market where biotech R\u0026amp;D spending still runs in the hundreds of billions of dollars globally each year.\u003c\/p\u003e\n\u003cp\u003eIf Ginkgo Bioworks Holdings, Inc. keeps converting collaborations into repeat programs, the revenue base can compound with biotech demand and stay one of its strongest growth lanes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIndustrial strain engineering\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIndustrial strain engineering is a Star if Ginkgo Bioworks turns faster-designed microbes into real sales, because replacing petroleum inputs with biological ones targets a large, high-growth chemicals market. The fit is strong, but Star status still depends on commercial scale, not just platform breadth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-growth sustainable chemicals angle\u003c\/li\u003e\n\u003cli\u003eBiology can replace oil-based feedstocks\u003c\/li\u003e\n\u003cli\u003eNeeds faster commercialization to stay Star\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAgricultural biologicals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAgricultural biologicals fit a large, fast-growing market: global biocontrol and biofertilizer use is rising as growers cut chemical inputs and protect yields. Ginkgo Bioworks already sells cell-programming services to ag partners, so more adoption could turn this into a real growth driver.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCrop protection demand keeps expanding\u003c\/li\u003e\n\u003cli\u003eYield gains support farmer adoption\u003c\/li\u003e\n\u003cli\u003eGinkgo has an existing partner base\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGinkgo’s Star Lines: Biosecurity, Drug Discovery, and Ag Biologics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars at Ginkgo Bioworks Holdings, Inc. are the highest-growth lines tied to its cell engineering platform, especially drug discovery, Concentric biosecurity, and agricultural biologicals. The core foundry supported 2024 revenue of $189.3 million, but these units still need repeat wins and faster scale to stay Stars.\u003c\/p\u003e\n\u003cp\u003eConcentric fits best where pathogen monitoring budgets rise and contract volumes expand. Drug discovery and ag bio can scale from one platform across many programs, so each new partner can add revenue without a full new build.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar line\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform\u003c\/td\u003e\n\u003ctd\u003e2024 revenue: $189.3M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConcentric\u003c\/td\u003e\n\u003ctd\u003eFast-growing biosecurity demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDrug discovery\u003c\/td\u003e\n\u003ctd\u003eScales across many partners\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eGinkgo Bioworks BCG Matrix maps its synthetic biology units to guide invest, hold, or divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page BCG Matrix for Ginkgo Bioworks, neatly mapping each unit to ease strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a traceable source trail for Ginkgo Bioworks Holdings, Inc. that strengthens credibility and speeds investor due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRepeat government contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGinkgo Bioworks Holdings, Inc.’s biosecurity work taps repeat public-sector demand from agencies like BARDA and DARPA, so it is steadier than frontier biotech bets. These contracts are usually renewal-driven, not promotion-driven, which lowers demand swings. That makes them the closest thing to a recurring cash-flow base in Ginkgo Bioworks Holdings, Inc.’s portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished pharma services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGinkgo Bioworks Holdings, Inc.'s established pharma services fit a cash cow profile because repeat programs with trusted pharma partners can keep producing service fees, milestones, and follow-on work. In 2025, the business still leaned on mature collaborations rather than new venture bets, which usually means steadier near-term cash than platform R\u0026amp;D. The key sign is repeatability: once a workflow is proven, margins tend to improve as the same service gets reused.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFoundry service retainers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFoundry service retainers fit Ginkgo Bioworks Holdings, Inc.’s cash cow profile because some clients keep using the foundry as an outsourced R and D base, which turns the same platform into repeat revenue. That model usually grows slower than new market bets, but it can hold margins steadier because the infrastructure is already in place. For Ginkgo Bioworks Holdings, Inc., the value is in recurring use, not one-off projects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eData and codebase access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGinkgo Bioworks Holdings, Inc. treats its internal strain library and biological data as reusable assets, so one build can support many later projects. That makes Data and codebase access a classic Cash Cow: low-growth, but with high reuse and thin added cost when partners tap the same assets again. The latest filings still show a platform built to monetize prior work, not just fresh lab hours.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReuse drives revenue with low added cost\u003c\/li\u003e\n\u003cli\u003eStrain library compounds across partners\u003c\/li\u003e\n\u003cli\u003eData assets fit Cash Cow logic\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLifecycle partner milestones\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLifecycle partner milestones are Ginkgo Bioworks Holdings, Inc.'s cash cow-style link: mature deals can keep paying after the first build phase. In 2025, Ginkgo still had large operating losses, so these milestone receipts matter because they are one of the few nearer-term cash sources. They are not a growth rocket, but they can help fund R\u0026amp;D and overhead.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMature deals can trigger repeat milestone cash.\u003c\/li\u003e\n\u003cli\u003eHelps offset 2025 operating losses.\u003c\/li\u003e\n\u003cli\u003eNear-term funding, not high-growth revenue.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGinkgo’s Cash Cows Keep the Lights On\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGinkgo Bioworks Holdings, Inc.’s cash cows are the repeat-use parts of the business: biosecurity contracts, mature pharma services, and the foundry base. They rely on renewals, milestones, and reused data assets, so they add steadier cash than new R\u0026amp;D bets. That matters in 2025, when the model still leaned on established work to fund losses and overhead.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash cow area\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003cth\u003eCash effect\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosecurity\u003c\/td\u003e\n\u003ctd\u003eRenewal-driven public contracts\u003c\/td\u003e\n\u003ctd\u003eMore stable receipts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharma services\u003c\/td\u003e\n\u003ctd\u003eRepeat partner programs\u003c\/td\u003e\n\u003ctd\u003eService fees and milestones\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFoundry and data\u003c\/td\u003e\n\u003ctd\u003eReusable platform assets\u003c\/td\u003e\n\u003ctd\u003eLow-added-cost reuse\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eGinkgo Bioworks Holdings, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Ginkgo Bioworks Holdings, Inc. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No demo pages, no watermarks, and no placeholders—just the full, ready-to-use report. Once purchased, the file is instantly available for download and use in your analysis, presentation, or strategy work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCOVID testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCOVID testing is a Dog in Ginkgo Bioworks Holdings, Inc. BCG Matrix Analysis: pandemic demand has structurally faded, with test volumes now well over 90% below peak levels. It has low share and low growth, so it no longer drives meaningful revenue or strategic upside for Company Name.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOne-off pilot projects\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOne-off pilot projects can absorb Ginkgo Bioworks Holdings, Inc. lab time and sales effort without scaling into repeat work. In 2024, Ginkgo Bioworks Holdings, Inc. reported about $227 million of revenue, showing how much depends on limited project flow. If a customer does not renew, the value stays small, and the projects can look busy while adding little long-term return.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-core consumer pilots\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNon-core consumer pilots fit Dogs because consumer biology is brand-led and crowded, so Ginkgo Bioworks Holdings, Inc. does not get strong scale advantage. In 2024, Ginkgo Bioworks Holdings, Inc. reported about $203 million in revenue, but consumer bets still need a partner willing to fund launch volume. Without that commitment, these pilots usually stay small and low-return.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDiscontinued venture bets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGinkgo Bioworks Holdings, Inc. has kept many venture-style bets in house, but several never scaled into material revenue. In 2025, the Company still reported heavy operating losses and used cash on R\u0026amp;D and platform programs, so weak bets can drain time and capital fast. That is classic dog behavior: low return, high drag.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUnscaled bets consume cash and staff time.\u003c\/li\u003e\n\u003cli\u003eWeak commercialization limits returns.\u003c\/li\u003e\n\u003cli\u003ePortfolio pruning matters for focus.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCommodity enzyme work\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCommodity enzyme work is a Dog for Ginkgo Bioworks Holdings, Inc. because basic enzyme optimization gets price-competitive fast, so gross margin stays thin and repeat volume is hard to lock in. That is a weak fit versus higher-value engineering programs, especially when Ginkgo Bioworks Holdings, Inc. still reported $178.2 million of 2025 revenue in its latest filing period and needs work with clearer pricing power.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFast commoditization cuts pricing power.\u003c\/li\u003e\n\u003cli\u003eThin margins hurt unit economics.\u003c\/li\u003e\n\u003cli\u003eRepeat orders are less certain.\u003c\/li\u003e\n\u003cli\u003eHigher-value programs fit better.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGinkgo’s DOGS: Low-Growth Bets Still Dragging Returns\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDOGS at Ginkgo Bioworks Holdings, Inc. are low-growth, low-share bets that burn time and cash without scaling. COVID testing, one-off pilots, and commodity enzyme work fit this bucket because demand is weak, pricing power is thin, and repeat orders are uncertain. In 2025, Company Name still reported $178.2 million of revenue, but weak programs kept dragging returns.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog\u003c\/th\u003e\n\u003cth\u003eWhy\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOVID testing\u003c\/td\u003e\n\u003ctd\u003eFaded demand\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90% below peak\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOne-off pilots\u003c\/td\u003e\n\u003ctd\u003eNo scale\u003c\/td\u003e\n\u003ctd\u003e$178.2m revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAI-driven design tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGinkgo Bioworks is pushing AI-driven design tools deeper into cell engineering, but this is still a Question Mark in the BCG matrix. The segment sits in a fast-growing market, yet Ginkgo has not shown clear share leadership, so adoption has to rise fast or it stays experimental. In 2025, scaling the platform matters more than model quality alone.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTherapeutic cell programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTherapeutic cell programs fit the question mark box: cell and gene therapy demand is still growing at roughly 20%+ a year, but Ginkgo Bioworks Holdings, Inc. has only a small commercial share versus specialist biotech and CDMO players. Ginkgo Bioworks Holdings, Inc. has the technical base, yet its FY2025\/2026 traction is still limited, so the upside is real but not proven. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFood ingredient engineering\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFood ingredient engineering is a Question Mark for Ginkgo Bioworks Holdings, Inc.: demand is rising as brands chase resilient, non-animal supply chains, but commercial scale is still unproven. Ginkgo’s 2024 revenue was about $227 million, and the unit still needs heavy R\u0026amp;D before it can convert engineered strains into repeatable ingredient output. If pilot wins turn into large contracts, this could move toward Star status; right now, it is still a capital-intensive bet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpecialty chemical programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSpecialty chemical programs sit in a high-potential, low-share zone: bio-based inputs can replace petrochemical feedstocks across coatings, surfactants, and materials, a market tied to global chemicals sales above $5 trillion. Ginkgo Bioworks can support many partners, but it has not shown category dominance, so the upside is real and the share is still uncertain.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge addressable market\u003c\/li\u003e\n\u003cli\u003ePlatform can participate\u003c\/li\u003e\n\u003cli\u003eCategory leadership not proven\u003c\/li\u003e\n\u003cli\u003eShare remains uncertain\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNew geographic expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNew geographic expansion is a Question Mark for Ginkgo Bioworks Holdings, Inc. because overseas scaling could widen partner access, but the company still has a modest footprint beyond the U.S. It can win new demand in Europe and Asia, yet each market needs local sales, compliance, and partner-building spend before it can gain share.\u003c\/p\u003e\n\u003cp\u003eThat makes the upside real but uneven: more markets can lift platform use, but near-term margins may stay under pressure while Ginkgo invests to expand. In BCG terms, this is a growth bet, not a cash engine.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore partners, but limited global reach.\u003c\/li\u003e\n\u003cli\u003eGrowth needs local spend and setup.\u003c\/li\u003e\n\u003cli\u003eShare gains are not yet proven.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGinkgo Bioworks: High-Upside Question Mark, Thin Proof, Heavy Cash Burn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks at Ginkgo Bioworks Holdings, Inc. are still high-upside, low-share bets: AI design, cell therapy, food ingredients, and specialty chemicals all sit in fast-growing markets, but commercial proof is thin. FY2025 traction is still not strong enough to call leadership, and 2024 revenue was about $227 million. The upside is real, but so is the cash burn.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue base\u003c\/td\u003e\n\u003ctd\u003eStill small\u003c\/td\u003e\n\u003ctd\u003eAbout $227 million in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket fit\u003c\/td\u003e\n\u003ctd\u003eHigh growth\u003c\/td\u003e\n\u003ctd\u003eCell therapy, food, chemicals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBCG view\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003eShare not yet proven\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234351882505,"sku":"dna-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/dna-bcg-matrix.webp?v=1785716940","url":"https:\/\/dcfanalyst.com\/products\/dna-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}